Skip to main content
PMC home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1995;73(5):691–701.

Modern treatment of haemophilia.

E Berntorp 1, V Boulyjenkov 1, D Brettler 1, M Chandy 1, P Jones 1, C Lee 1, J Lusher 1, P Mannucci 1, I Peak 1, K Rickard 1, et al.
PMCID: PMC2486807  PMID: 8846496

Abstract

Many rapid advances have been made in the diagnosis and therapy of haemophilia. Nevertheless, the condition still poses problems and challenges (e.g., joint disease, transfusion-transmitted diseases, inhibitors, provision of care in developing countries, and education and cost issues). WHO and the World Federation of Hemophilia held a joint meeting in Geneva, on 21-23 March 1994, to discuss and review current and future approaches to the management of haemophilia and its complications, including prospects for genetic technology and gene therapy in developed and developing countries. The present review article summarizes the discussions and recommendations made by the participants.

Full text

PDF
695

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brettler D. B., Forsberg A. D., Levine P. H., Aledort L. M., Hilgartner M. W., Kasper C. K., Lusher J. M., McMillan C., Roberts H. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med. 1989 Jun;149(6):1381–1385. [PubMed] [Google Scholar]
  2. Carlsson M., Berntorp E., Björkman S., Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol. 1993 Oct;51(4):247–252. doi: 10.1111/j.1600-0609.1993.tb00638.x. [DOI] [PubMed] [Google Scholar]
  3. Ehrenforth S., Kreuz W., Scharrer I., Linde R., Funk M., Güngör T., Krackhardt B., Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992 Mar 7;339(8793):594–598. doi: 10.1016/0140-6736(92)90874-3. [DOI] [PubMed] [Google Scholar]
  4. Guillaume T. Parvovirus B19 and blood products. Lancet. 1994 Apr 30;343(8905):1101–1101. [PubMed] [Google Scholar]
  5. Kasper C. K., Lusher J. M. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee. Transfusion. 1993 May;33(5):422–434. doi: 10.1046/j.1537-2995.1993.33593255605.x. [DOI] [PubMed] [Google Scholar]
  6. Lefrère J. J., Mariotti M., Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet. 1994 Jan 22;343(8891):211–212. doi: 10.1016/s0140-6736(94)90993-8. [DOI] [PubMed] [Google Scholar]
  7. Lusher J., Kessler C., Laurian Y., Pierce G. Viral contamination of blood products. Lancet. 1994 Aug 6;344(8919):405–406. [PubMed] [Google Scholar]
  8. Mannucci P. M. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang. 1993;64(4):197–203. doi: 10.1111/j.1423-0410.1993.tb03055.x. [DOI] [PubMed] [Google Scholar]
  9. Martinowitz U., Schulman S., Gitel S., Horozowski H., Heim M., Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol. 1992 Dec;82(4):729–734. doi: 10.1111/j.1365-2141.1992.tb06951.x. [DOI] [PubMed] [Google Scholar]
  10. Nilsson I. M., Berntorp E. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX. Prog Clin Biol Res. 1990;324:69–78. [PubMed] [Google Scholar]
  11. Nilsson I. M., Berntorp E., Löfqvist T., Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992 Jul;232(1):25–32. doi: 10.1111/j.1365-2796.1992.tb00546.x. [DOI] [PubMed] [Google Scholar]
  12. Peerlinck K., Arnout J., Gilles J. G., Saint-Remy J. M., Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost. 1993 Feb 1;69(2):115–118. [PubMed] [Google Scholar]
  13. Peerlinck K., Vermylen J. Acute hepatitis A in patients with haemophilia A. Lancet. 1993 Jan 16;341(8838):179–179. doi: 10.1016/0140-6736(93)90044-h. [DOI] [PubMed] [Google Scholar]
  14. Seremetis S. V., Aledort L. M., Bergman G. E., Bona R., Bray G., Brettler D., Eyster M. E., Kessler C., Lau T. S., Lusher J. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet. 1993 Sep 18;342(8873):700–703. doi: 10.1016/0140-6736(93)91706-r. [DOI] [PubMed] [Google Scholar]
  15. Sultan Y., White G. C., Aronstam A., Bosser C., Brackmann H. H., Brochier G., Gormsen J., Mariani G., Roberts H. R., Scarabin Y. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII. Nouv Rev Fr Hematol. 1986;28(2):85–89. [PubMed] [Google Scholar]
  16. Troisi C. L., Hollinger F. B., Hoots W. K., Contant C., Gill J., Ragni M., Parmley R., Sexauer C., Gomperts E., Buchanan G. A multicenter study of viral hepatitis in a United States hemophilic population. Blood. 1993 Jan 15;81(2):412–418. [PubMed] [Google Scholar]
  17. Watson H. G., Ludlam C. A., Rebus S., Zhang L. Q., Peutherer J. F., Simmonds P. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol. 1992 Apr;80(4):514–518. doi: 10.1111/j.1365-2141.1992.tb04566.x. [DOI] [PubMed] [Google Scholar]
  18. Williams M. D., Cohen B. J., Beddall A. C., Pasi K. J., Mortimer P. P., Hill F. G. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang. 1990;58(3):177–181. doi: 10.1111/j.1423-0410.1990.tb02086.x. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES